加速新型结核病药物组合从 II 期到 III 期试验的转变：新技术和创新设计。
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
机构信息
University of Liverpool, Liverpool, United Kingdom.
Radboud University, Nijmegen, the Netherlands.
出版信息
PLoS Med. 2019 Jul 9;16(7):e1002851. doi: 10.1371/journal.pmed.1002851. eCollection 2019 Jul.
Abstract
Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.
摘要
杰兰特·戴维斯等人探讨了创新的早期临床试验方法和技术在降低结核病药物开发风险和加快药物开发速度方面的潜力。
相似文献
1
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
PLoS Med. 2019 Jul 9;16(7):e1002851. doi: 10.1371/journal.pmed.1002851. eCollection 2019 Jul.
2
Adaptive clinical trials in tuberculosis: applications, challenges and solutions.
Int J Tuberc Lung Dis. 2015 Jun;19(6):626-34. doi: 10.5588/ijtld.14.0988.
3
Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.
PLoS Med. 2019 Jul 5;16(7):e1002842. doi: 10.1371/journal.pmed.1002842. eCollection 2019 Jul.
4
Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.
PLoS Med. 2019 Jul 12;16(7):e1002850. doi: 10.1371/journal.pmed.1002850. eCollection 2019 Jul.
5
Advances in clinical trial design: Weaving tomorrow's TB treatments.
PLoS Med. 2020 Feb 27;17(2):e1003059. doi: 10.1371/journal.pmed.1003059. eCollection 2020 Feb.
6
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.
PLoS Med. 2019 Sep 6;16(9):e1002915. doi: 10.1371/journal.pmed.1002915. eCollection 2019 Sep.
7
Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration.
Clin Infect Dis. 1992 Nov;15 Suppl 1:S282-95. doi: 10.1093/clind/15.supplement_1.s282.
8
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar.
9
Innovative trial designs are practical solutions for improving the treatment of tuberculosis.
J Infect Dis. 2012 May 15;205 Suppl 2:S250-7. doi: 10.1093/infdis/jis041. Epub 2012 Mar 22.
10
A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project.
Trials. 2012 May 18;13:61. doi: 10.1186/1745-6215-13-61.
引用本文的文献
1
AI-driven discovery of synergistic drug combinations against pancreatic cancer.
Nat Commun. 2025 Apr 29;16(1):4020. doi: 10.1038/s41467-025-56818-6.
2
The importance of getting the dose right in the treatment of tuberculosis.
Breathe (Sheff). 2025 Mar 18;21(1):240177. doi: 10.1183/20734735.0177-2024. eCollection 2025 Jan.
3
Accelerating TB regimen development: introducing FAST-TB.
IJTLD Open. 2024 Nov 1;1(11):483-485. doi: 10.5588/ijtldopen.24.0333. eCollection 2024 Nov.
4
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.
Nat Rev Drug Discov. 2024 May;23(5):381-403. doi: 10.1038/s41573-024-00897-5. Epub 2024 Feb 28.
5
High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance.
PLoS Comput Biol. 2023 Apr 13;19(4):e1011000. doi: 10.1371/journal.pcbi.1011000. eCollection 2023 Apr.
6
Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies.
Front Pharmacol. 2022 Dec 15;13:1032875. doi: 10.3389/fphar.2022.1032875. eCollection 2022.
7
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0089822. doi: 10.1128/aac.00898-22. Epub 2022 Nov 15.
8
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.
Pharmaceuticals (Basel). 2022 Oct 26;15(11):1321. doi: 10.3390/ph15111321.
9
Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.
PLoS One. 2022 Jul 25;17(7):e0271102. doi: 10.1371/journal.pone.0271102. eCollection 2022.
10
Making cough count in tuberculosis care.
Commun Med (Lond). 2022 Jul 6;2:83. doi: 10.1038/s43856-022-00149-w. eCollection 2022.
本文引用的文献
1
Advances in clinical trial design for development of new TB treatments: A call for innovation.
PLoS Med. 2019 Mar 22;16(3):e1002769. doi: 10.1371/journal.pmed.1002769. eCollection 2019 Mar.
2
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5.
3
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666. doi: 10.1164/rccm.201712-2524OC.
4
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01054-17. Print 2017 Nov.
5
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.
Clin Transl Sci. 2017 Sep;10(5):366-379. doi: 10.1111/cts.12472. Epub 2017 May 31.
6
Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials.
Clin Infect Dis. 2017 Jul 1;65(1):46-54. doi: 10.1093/cid/cix247.
7
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2.
8
Target regimen profiles for treatment of tuberculosis: a WHO document.
Eur Respir J. 2017 Jan 25;49(1). doi: 10.1183/13993003.02352-2016. Print 2017 Jan.
9
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.
10
Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.
J Clin Microbiol. 2016 Dec;54(12):3028-3033. doi: 10.1128/JCM.01313-16. Epub 2016 Oct 12.
Zotero 插件